Vimarsana
Biggest News Aggregation in the World

Page 6 - Stat Facts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stat Facts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stat Facts Today - Breaking & Trending Today

ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer - Vimarsana News

ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...

Source: afp.com
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Enhertu approved in EU for gastric cancer - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Enhertu approved in EU for gastric cancer

Investegate announcements from AstraZeneca PLC, Enhertu approved in EU for gastric cancer

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas - Vimarsana News

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in - Vimarsana News

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in

COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...

Genmab A/S: Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting - Vimarsana News

Genmab A/S: Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage